The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
The impact of type 2 diabetes mellitus on prognosis of non-small cell lung cancer with brain metastases
Author(s): 
Pages: 265-269
Year: Issue:  3
Journal: Chinese Journal of Neurosurgery

Keyword:  Carcinomanon-small-cell lungDiabetes mellitustype 2PrognosisBrain metastasis;
Abstract: Objective To investigate the impact of type 2 diabetes mellitus (DM) on prognosis of non-small cell lung cancer with brain metastases.Methods We retrospectively reviewed the clinical data of 406 patients,who were diagnosed as non-small cell lung cancer with brain metastases and admitted to the departments of brain tumor,radiation therapy,pulmonary medicine and pulmonary surgery at Tianjin University Cancer Institute & Hospital from October 2010 to May 2015.Log-rank analysis and Cox regression model were used to identify prognostic factors of non-small cell lung cancer with brain metastases and the impact of type 2 DM on the overall survival (OS) and progression-free survival (PFS).Results Univariate analysis of OS revealed that age,lymph node staging,DM,chemotherapy,Karnofsky performance score had statistical significance (all P < 0.05).Univariate analysis of PFS revealed that lymph node staging,DM,chemotherapy had statistical significance (all P < 0.05).Multivariate analysis showed that presence of DM (OR,0.203,95% CI0.067-0.618,P=0.005),lymph node staging (OR,0.573,95% CI 0.420-0.781,P<0.001) and age (OR,0.609,95% CI 0.409-0.907,P =0.015) were considered independent prognostic factors for OS (P < 0.05).In addition,DM (OR,0.317,95 % CI 0.112-0.900,P =0.031),lymph node staging (OR,0.723,95% CI 0.556-0.941,P =0.016) and chemotherapy (OR,0.450,95% CI 0.253-0.798,P =0.006) were identified as independent prognostic factors for PFS (P < 0.05).Conclusion It is suggested that a history of type 2 DM might be correlated with increased OS and PFS in patients with NSCLC with brain metastases.
Related Articles
No related articles found